FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387263223> ?p ?o ?g. }

• W4387263223 abstract "<p>NF-κB pathway activation via RelA phosphorylation and binding is enhanced in hormone-deprived conditions. <b>A,</b> Immunoblot of whole-cell lysates for the NF-κB subunits, RelA and RelB, and ER in MCF7 cells grown with E2 10 nmol/L or in HD conditions in response to IFNγ 10 ng/mL stimulation. <b>B,</b> Whole-cell lysate immunoblots of ER, RelA, and phospho-RelA (Ser536) in MCF7 cells. Hormone-deprived cells were stimulated with E2 (10 nmol/L) for 4 days. Protein was extracted every 24 hours. GAPDH was used as a loading control. <b>C,</b> Tornado plots of RelA binding sites in HD cells or treated with 10 nmol/L E2 with or without IFNγ stimulation (10 ng/mL for 1 hour). <b>D,</b> Volcano plot showing differential expression from RNA-seq of MCF7 cells in HD conditions versus E2-treated conditions. Blue dots (True), genes that are differentially expressed based on RNA-seq and predicted to be regulated by RelA based on RelA ChIP-seq and BETA minus analysis. Orange dots (false), genes that are differentially expressed between HD and E2 conditions but not predicted to be regulated by RelA based on the RelA ChIP-seq data. The <i>P</i> value represents the significance of the association between RelA ChIP-seq and RNA-seq up HD (<i>P</i> = 1.9 E−11) or down in HD (<i>P</i> = 0.156) compared with E2-stimulated cells without IFNγ based on BETA basic. <b>E,</b> GSVA of the HD_RelA gene set (541 genes) in primary ER⁺ breast cancers pre- and post-neoadjuvant treatment with an AI. <b>F</b> and <b>G,</b> RNA-seq differential expression after RelA KO compared with control. Volcano plot highlighting genes differentially expressed between RelA KOs and RelA WT cells grown in HD conditions (<b>F</b>), treated with fulvestrant (10 nmol/L; <b>G</b>), or grown in E2 conditions (<b>H</b>) for 72 hours and stimulated with IFNγ (10 ng/mL) for the last 6 hours (h). <i>n</i>, number of genes differentially expressed. <b>I,</b> RelA ChIP-seq tracks showing examples of RelA peaks at the promoter region of IFNγ-associated genes in MCF7 cells grown in the presence of E2 or in HD conditions and stimulated ± IFNγ (10 ng/mL) for one hour. <b>J,</b> mRNA expression levels of ICAM1, HLA-A, TAP1, B2M, and CXCL10 in E2 and HD conditions without and with RELA silencing KO after 6 hours of IFNγ stimulation. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001. Error bars, mean ± SD of at least two replicates per each KO. Two-way ANOVA.</p>" @default.
• W4387263223 created "2023-10-03" @default.
• W4387263223 creator A5001315712 @default.
• W4387263223 creator A5005699273 @default.
• W4387263223 creator A5006077440 @default.
• W4387263223 creator A5006906416 @default.
• W4387263223 creator A5008111913 @default.
• W4387263223 creator A5008682981 @default.
• W4387263223 creator A5010234110 @default.
• W4387263223 creator A5012991748 @default.
• W4387263223 creator A5017174066 @default.
• W4387263223 creator A5020035024 @default.
• W4387263223 creator A5022422153 @default.
• W4387263223 creator A5024648766 @default.
• W4387263223 creator A5026132340 @default.
• W4387263223 creator A5027326315 @default.
• W4387263223 creator A5029062544 @default.
• W4387263223 creator A5030750380 @default.
• W4387263223 creator A5037645425 @default.
• W4387263223 creator A5039071000 @default.
• W4387263223 creator A5041427080 @default.
• W4387263223 creator A5042549348 @default.
• W4387263223 creator A5043143519 @default.
• W4387263223 creator A5047701430 @default.
• W4387263223 creator A5051714606 @default.
• W4387263223 creator A5053368670 @default.
• W4387263223 creator A5053695772 @default.
• W4387263223 creator A5053819517 @default.
• W4387263223 creator A5055038052 @default.
• W4387263223 creator A5055378234 @default.
• W4387263223 creator A5059400884 @default.
• W4387263223 creator A5060353514 @default.
• W4387263223 creator A5062515397 @default.
• W4387263223 creator A5064188148 @default.
• W4387263223 creator A5066070097 @default.
• W4387263223 creator A5069056507 @default.
• W4387263223 creator A5069182089 @default.
• W4387263223 creator A5081025221 @default.
• W4387263223 creator A5082128924 @default.
• W4387263223 creator A5083901548 @default.
• W4387263223 creator A5085458148 @default.
• W4387263223 creator A5090611170 @default.
• W4387263223 creator A5016265992 @default.
• W4387263223 date "2023-10-02" @default.
• W4387263223 modified "2023-10-03" @default.
• W4387263223 title "Figure 5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer" @default.
• W4387263223 doi "https://doi.org/10.1158/0008-5472.24229144.v1" @default.
• W4387263223 hasPublicationYear "2023" @default.
• W4387263223 type Work @default.
• W4387263223 citedByCount "0" @default.
• W4387263223 crossrefType "posted-content" @default.
• W4387263223 hasAuthorship W4387263223A5001315712 @default.
• W4387263223 hasAuthorship W4387263223A5005699273 @default.
• W4387263223 hasAuthorship W4387263223A5006077440 @default.
• W4387263223 hasAuthorship W4387263223A5006906416 @default.
• W4387263223 hasAuthorship W4387263223A5008111913 @default.
• W4387263223 hasAuthorship W4387263223A5008682981 @default.
• W4387263223 hasAuthorship W4387263223A5010234110 @default.
• W4387263223 hasAuthorship W4387263223A5012991748 @default.
• W4387263223 hasAuthorship W4387263223A5016265992 @default.
• W4387263223 hasAuthorship W4387263223A5017174066 @default.
• W4387263223 hasAuthorship W4387263223A5020035024 @default.
• W4387263223 hasAuthorship W4387263223A5022422153 @default.
• W4387263223 hasAuthorship W4387263223A5024648766 @default.
• W4387263223 hasAuthorship W4387263223A5026132340 @default.
• W4387263223 hasAuthorship W4387263223A5027326315 @default.
• W4387263223 hasAuthorship W4387263223A5029062544 @default.
• W4387263223 hasAuthorship W4387263223A5030750380 @default.
• W4387263223 hasAuthorship W4387263223A5037645425 @default.
• W4387263223 hasAuthorship W4387263223A5039071000 @default.
• W4387263223 hasAuthorship W4387263223A5041427080 @default.
• W4387263223 hasAuthorship W4387263223A5042549348 @default.
• W4387263223 hasAuthorship W4387263223A5043143519 @default.
• W4387263223 hasAuthorship W4387263223A5047701430 @default.
• W4387263223 hasAuthorship W4387263223A5051714606 @default.
• W4387263223 hasAuthorship W4387263223A5053368670 @default.
• W4387263223 hasAuthorship W4387263223A5053695772 @default.
• W4387263223 hasAuthorship W4387263223A5053819517 @default.
• W4387263223 hasAuthorship W4387263223A5055038052 @default.
• W4387263223 hasAuthorship W4387263223A5055378234 @default.
• W4387263223 hasAuthorship W4387263223A5059400884 @default.
• W4387263223 hasAuthorship W4387263223A5060353514 @default.
• W4387263223 hasAuthorship W4387263223A5062515397 @default.
• W4387263223 hasAuthorship W4387263223A5064188148 @default.
• W4387263223 hasAuthorship W4387263223A5066070097 @default.
• W4387263223 hasAuthorship W4387263223A5069056507 @default.
• W4387263223 hasAuthorship W4387263223A5069182089 @default.
• W4387263223 hasAuthorship W4387263223A5081025221 @default.
• W4387263223 hasAuthorship W4387263223A5082128924 @default.
• W4387263223 hasAuthorship W4387263223A5083901548 @default.
• W4387263223 hasAuthorship W4387263223A5085458148 @default.
• W4387263223 hasAuthorship W4387263223A5090611170 @default.
• W4387263223 hasBestOaLocation W43872632231 @default.
• W4387263223 hasConcept C126322002 @default.
• W4387263223 hasConcept C134018914 @default.
• W4387263223 hasConcept C153911025 @default.
• W4387263223 hasConcept C185592680 @default.
• W4387263223 hasConcept C502942594 @default.
• W4387263223 hasConcept C71924100 @default.
• W4387263223 hasConcept C86803240 @default.

• next